secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenetic Biosciences, Inc. (XBIO)
CIK:        0001534525
Form:       8-K
Filed at:   2024-03-22T23:59:59+00:00
Accession:  0001683168-24-001606
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenetic Biosciences reports FY2023 net loss of $4.1M; cash at $9.0M
-------------------------------------------------------------------

- Net loss of $4.1M for year ended Dec 31, 2023; R&D expenses down 26.7% to $3.5M.
- Royalty payments from Takeda sublicense rose 48.8% to $2.5M in 2023.
- Cash and cash equivalents of $9.0M at year-end to fund operations.
- Advancing DNase-based oncology platform targeting pancreatic carcinoma toward Phase 1 trial.
- Entered research funding and material transfer agreement with University of Virginia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534525/000168316824001606/0001683168-24-001606-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534525/000168316824001606/xenetic_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-001606

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer